It turned out that dual insulin-like growth factor 1 receptor/insulin receptor (IGF1R/IR) kinase inhibitors, BMS-754807 (BMS) and linsitinib (LIN), effectively inhibited the proliferation of glioma cells without negatively affecting CAR-T cells. Here, IGF1R is linked to glioma.